New Risk • May 27
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£0 net loss next year). Market cap is less than US$100m (€14.4m market cap, or US$16.7m). New Risk • May 23
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£145k Forecast net loss in 1 year: UK£0 This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£0 net loss next year). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (€15.1m market cap, or US$17.5m). Board Change • May 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. CFO, Company Secretary & Director Lachlan Smith was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. 공고 • Jan 30
RUA Life Sciences plc, Annual General Meeting, Mar 17, 2026 RUA Life Sciences plc, Annual General Meeting, Mar 17, 2026. Location: gailes hotel, marine drive, irvine, ayrshire ka11 5ae, United Kingdom 공고 • Sep 10
RUA Life Sciences plc (AIM:RUA) acquired Analytic Biosurgical Solutions from IPSA Group for €0.08 million. RUA Life Sciences plc (AIM:RUA) acquired Analytic Biosurgical Solutions from IPSA Group for €0.08 million on September 9, 2024. The gross assets of Abiss at December 31, 2023 were €2.265 million. Revenue in the year to December 31, 2023 was €2.159 million. Loss before tax was €0.352 million after depreciation and amortization charges of €0.537 million. In the year to December 31, 2023, Abiss had net positive cash flow of €0.223 million and cash balances of €0.279 million at the year end. Net Assets/Shareholders Funds at December 31, 2023 were €1.624 million. Non-current liabilities totaled €0.64 million at December 31, 2023. Giles Balleny, Dan Hodkinson, Charlie Combe, Michael Johnson of Cavendish Capital Markets Limited acted as financial advisor to RUA Life Sciences plc.
RUA Life Sciences plc (AIM:RUA) completed the acquisition of Analytic Biosurgical Solutions from IPSA Group on September 9, 2024. Reported Earnings • Jul 25
Full year 2024 earnings released: UK£0.043 loss per share (vs UK£0.09 loss in FY 2023) Full year 2024 results: UK£0.043 loss per share (improved from UK£0.09 loss in FY 2023). Revenue: UK£2.19m (flat on FY 2023). Net loss: UK£1.44m (loss narrowed 28% from FY 2023). Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings. 공고 • Jul 25
RUA Life Sciences plc, Annual General Meeting, Aug 27, 2024 RUA Life Sciences plc, Annual General Meeting, Aug 27, 2024. Location: gailes hotel, marine drive, irvine, ayrshire ka11 5ae, United Kingdom New Risk • Jul 15
New major risk - Revenue and earnings growth Earnings have declined by 29% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 29% per year over the past 5 years. Shareholders have been substantially diluted in the past year (180% increase in shares outstanding). Market cap is less than US$10m (€8.04m market cap, or US$8.76m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Revenue is less than US$5m (UK£1.9m revenue, or US$2.4m). New Risk • Jul 05
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (32% average weekly change). Shareholders have been substantially diluted in the past year (180% increase in shares outstanding). Market cap is less than US$10m (€8.06m market cap, or US$8.72m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (UK£277k net loss in 2 years). Revenue is less than US$5m (UK£1.9m revenue, or US$2.4m). 공고 • Apr 05
RUA Life Sciences plc Provides Revenue Guidance for the Year Ended 31 March 2024 RUA Life Sciences plc provided revenue guidance for the year ended 31 March 2024. The first half of the financial year was impacted by operational issues, resulting in the delayed shipment of products from the Contract Manufacturing business. As anticipated, the revenue shortfall experienced during first half has been fully compensated by a strong second half performance. As a result, the Company expects to report, subject to audit, fiscal year 2024 revenue of £2.2 million, which is in line with market expectations. 공고 • Dec 20
Rua Life Sciences plc Provides an Update on Recent Developments of the Rua Leaflet Composite RUA Life Sciences provided an update on recent developments of the RUA leaflet composite. The objective for RUA Structural Heart during 2023 was to evaluate heart valve leaflet material and compare the performance of 100% polymeric valves with the novel composite developed by the Group. The computational modelling of the composite material at the design stage suggested that its mechanical properties would be ideal for heart valve leaflets. Testing undertaken by RUA has demonstrated: Flex fatigue stability over 400m cycles Durability as a heart valve leaflet over 200m cycles; Rem remarkable tensile strength properties exceeding both base fabric and polymer; Similar tensile strength in multiple directions; Highly flexible allowing improved valve efficiency; Narrow crimping profile allowing TAVR benefits; Retention of ElastEon blood contacting properties such as calcification and thrombogenicity; Material very stable with no delamination during testing and high tear resistance. Patient protection for the material has now been sought and coupled with the testing results achieved; RUA is now seeking to commercialise the RUA composite material as an alternative to animal tissue used in the manufacture of heart valves. Engagement with the industry has been positive and, as previously announced, a major heart valve company has approached the Company to undertake its own tests and has now entered into a material testing agreement (MTA) in order to do so. While there can be no certainty that the parties will progress to an agreement, an MTA is the preliminary step to further collaboration. Reported Earnings • Dec 20
First half 2024 earnings released: UK£0.046 loss per share (vs UK£0.052 loss in 1H 2023) First half 2024 results: UK£0.046 loss per share (improved from UK£0.052 loss in 1H 2023). Revenue: UK£794.0k (down 28% from 1H 2023). Net loss: UK£1.01m (loss narrowed 12% from 1H 2023). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings. Breakeven Date Change • Dec 20
Forecast to breakeven in 2026 The 2 analysts covering RUA Life Sciences expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of UK£435.0k in 2026. Average annual earnings growth of 73% is required to achieve expected profit on schedule. New Risk • Dec 19
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 1.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (45% average weekly change). Earnings are forecast to decline by an average of 1.2% per year for the foreseeable future. Market cap is less than US$10m (€2.87m market cap, or US$3.13m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£277k net loss in 2 years). Revenue is less than US$5m (UK£2.2m revenue, or US$2.8m). 공고 • Dec 08
RUA Life Sciences plc has completed a Follow-on Equity Offering in the amount of £4.386302 million. RUA Life Sciences plc has completed a Follow-on Equity Offering in the amount of £4.386302 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 36,363,636
Price\Range: £0.11
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 727,272
Price\Range: £0.11
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,784,566
Price\Range: £0.11
Transaction Features: Regulation S; Subsequent Direct Listing 공고 • Dec 01
RUA Life Sciences plc has filed a Follow-on Equity Offering in the amount of £4.83 million. RUA Life Sciences plc has filed a Follow-on Equity Offering in the amount of £4.83 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 36,363,636
Price\Range: £0.11
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 727,272
Price\Range: £0.11
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 6,818,181
Price\Range: £0.11
Transaction Features: Regulation S; Subsequent Direct Listing Board Change • Sep 08
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Ian Ardill was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공고 • Sep 01
RUA Life Sciences plc Announces Iain Anthony, Director of Clinical and Regulatory Affairs Tenders His Resignation RUA Life Sciences plc announced that Iain Anthony, Director of Clinical and Regulatory Affairs has tendered his resignation from the Company in order to accept an opportunity elsewhere within the industry. Iain joined RUA in November 2021 and has overseen the building of the Regulatory and Quality teams together with further development of the vascular graft device and was instrumental in undertaking the Q-Sub process with the FDA which has recently concluded succesfully. Iain will step down from the board with immediate effect but will continue in his role as an employee for an appropriate handover period while the Board looks for his successor. Reported Earnings • Dec 13
First half 2023 earnings released: UK£0.051 loss per share (vs UK£0.059 loss in 1H 2022) First half 2023 results: UK£0.051 loss per share (improved from UK£0.059 loss in 1H 2022). Revenue: UK£1.10m (up 56% from 1H 2022). Net loss: UK£1.14m (loss narrowed 13% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 22% per year whereas the company’s share price has fallen by 27% per year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Ian Ardill was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공고 • Nov 15
RUA Life Sciences plc to Report First Half, 2023 Results on Dec 12, 2022 RUA Life Sciences plc announced that they will report first half, 2023 results on Dec 12, 2022 Reported Earnings • Jul 12
Full year 2022 earnings released: UK£0.093 loss per share (vs UK£0.082 loss in FY 2021) Full year 2022 results: UK£0.093 loss per share (down from UK£0.082 loss in FY 2021). Revenue: UK£1.63m (up 6.3% from FY 2021). Net loss: UK£2.07m (loss widened 43% from FY 2021). Over the next year, revenue is forecast to grow 8.7%, compared to a 8.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. 공고 • Jul 12
RUA Life Sciences plc, Annual General Meeting, Aug 16, 2022 RUA Life Sciences plc, Annual General Meeting, Aug 16, 2022, at 10:00 Coordinated Universal Time. Location: Riverside Lodge Hotel 46 Annick Road, Irvine Ayrshire United Kingdom 공고 • Jul 07
RUA Life Sciences plc to Report Fiscal Year 2022 Results on Jul 11, 2022 RUA Life Sciences plc announced that they will report fiscal year 2022 results on Jul 11, 2022 공고 • May 27
Rua Life Sciences plc Provides Earnings Guidance for the 12 Months to 31 March 2022 RUA Life Sciences plc provided earnings guidance for the 12 months to 31 March 2022. For the period, the company expected to have generated consolidated unaudited revenues of £1,625,000 (2021: £1,528,000), an increase of 6% over the same period in the previous year. Overall, loss before tax for the period is expected to have increased to £2,360,000 (2021: £1,594,000) which resulted from a combination of increased R&D activities and further investment in the infrastructure to support future growth. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Ian Ardill was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 21
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Ian Ardill was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Dec 17
First half 2022 earnings: EPS in line with analyst expectations despite revenue beat First half 2022 results: UK£0.059 loss per share (down from UK£0.038 loss in 1H 2021). Revenue: UK£708.0k (up 12% from 1H 2021). Net loss: UK£1.31m (loss widened 115% from 1H 2021). Revenue exceeded analyst estimates by 7.6%. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings. 공고 • Dec 15
RUA Life Sciences plc Announces the Submission by RUA Vascular to the US Food and Drug Administration of its Premarket Notification (510k) for A Range of Polymerically Sealed Vascular Grafts RUA Life Sciences plc announced the submission by RUA Vascular to the US Food and Drug Administration ("FDA") of its Premarket Notification (510k) for a range of polymerically sealed vascular grafts. After initial document review, the Company's regulatory team held an initial meeting with the FDA to discuss certain novel aspects of the RUA grafts and, as a result, mutually agreed to convert the 510k submission to a pre submission process, allowing the Company and the FDA to agree the additional data required to facilitate the 510k approval. The regulatory pathway has been extended and, as a result, RUA no longer anticipates first commercial sales of grafts to be achieved during the first quarter of 2022. A further update on the agreed process with the FDA and the likely new timelines for approval of the 510k will be made in due course. Board Change • Sep 13
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Ian Ardill was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 15
Full year 2021 earnings released: UK£0.082 loss per share (vs UK£0.056 loss in FY 2020) The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2021 results: Revenue: UK£1.53m (up 204% from FY 2020). Net loss: UK£1.45m (loss widened 78% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has increased by 27% per year, which means it is well ahead of earnings. 공고 • Jun 25
Rua Life Sciences Plc Provides Update on RUA Vascular RUA Life Sciences plc provided the following update on the regulatory application for the large bore vascular grafts in development by RUA Vascular. All results from both in vivo and in vitro testing have now been gathered and the submission pack for 510k application to the FDA has been prepared. Mechanical testing of the grafts indicate superior performance over the control. Pathology results from the six-month in vivo testing were normal giving the Board confidence that the grafts perform as anticipated. Is New 90 Day High Low • Jan 22
New 90-day high: €2.00 The company is up 32% from its price of €1.52 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 11% over the same period. 공고 • Jan 19
RUA Life Sciences Announces Directorate Changes RUA Life Sciences announced the appointments, with immediate effect, to the Board of Dr. Caroline Stretton, Group Chief Operating Officer of the Company, and Ian Ardill as a Non-Executive Director and Chair of the Audit Committee. Dr. Caroline Stretton who was appointed as Group Chief Operating Officer on 1 April 2020, following the Company's acquisition of RUA Medical Devices Limited ("RUA Medical"), joined RUA Medical in 2018 from prosthetic hand manufacturer, Touch Bionics Limited, where, prior to its sale in 2016 to Icelandic orthotic and prosthetic manufacturer Ossur, she was a key member of the leadership team responsible for Global Manufacturing, Operations, Quality and Customer Support. Previously, Caroline had been employed by a number of medical device and pharmaceutical companies in a variety of roles, most notably Ivax Pharmaceuticals (now Teva Pharmaceuticals), Ocutec Limited and Mpathy Medical Devices Limited, a surgical medical device company which achieved a multi-million pound exit to Danish surgical medical device manufacturer, Coloplast, in 2010. Ian Ardill has over 25 years' experience in senior financial positions, with the majority of that time being spent in medical devices and pharmaceuticals. He is currently Managing Director of Causeway Finance Associates Limited, a CFO and accountancy consultancy focussed in Life Sciences, which he founded in 2017. Previously, he was Chief Financial Officer of Diurnal Limited, which he joined in April 2015 ahead of the company's successful IPO on AIM in December 2015. Prior to that, Ian was Chief Financial Officer of two other listed companies. With Lombard Medical Technologies plc, from 2012 to 2015, he led the company financially through the late stages of FDA pre-market approval and the commencement of US commercial operations. On the financing front, he managed a £22 million fundraising on AIM and the company's IPO on NASDAQ raising $55 million. With Biocompatibles International plc, from 2003 to 2011, he played a leading role in transforming the company from a loss-making to a profitable enterprise with sales of £33 million. He also managed the company's sale to BTG Plc in 2011 for £177 million and two returns of capital to shareholders totaling £23 million. 공고 • Jan 01
Rua Life Sciences Plc, Annual General Meeting, Dec 30, 2020 Rua Life Sciences Plc, Annual General Meeting, Dec 30, 2020. Agenda: To consider allotment of ordinary shares for fundraising; to consider pre-emption rights fundraising; to consider allotment of ordinary shares, general authority; to consider pre-emption rights; and to consider pre-emption rights, acquisitions and specified investments. 공고 • Dec 31
Rua Life Sciences Plc has completed a Follow-on Equity Offering in the amount of £6.997826 million. Rua Life Sciences Plc has completed a Follow-on Equity Offering in the amount of £6.997826 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 5,831,522
Price\Range: £1.2
Transaction Features: Rights Offering; Subsequent Direct Listing 공고 • Dec 13
Rua Life Sciences plc Announces Resignation of Gordon Wright as Non-Executive Director RUA Life Sciences plc announced that Gordon Wright has resigned as a non-executive Director of the Company with effect from 10 December 2020. The Directors wish to thank Gordon for his support and guidance over the years and look forward to working with him in his new role as Honorary Life President. Is New 90 Day High Low • Nov 24
New 90-day high: €1.82 The company is up 39% from its price of €1.31 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. 공고 • Oct 03
Rua Life Sciences Plc Auditor Raises 'Going Concern' Doubt Rua Life Sciences Plc filed its Annual on Jul 16, 2020 for the period ending Mar 31, 2020. In this report its auditor, Grant Thornton, gave an unqualified opinion expressing doubt that the company can continue as a going concern. 공고 • Jul 05
Rua Life Sciences Plc to Report Fiscal Year 2020 Final Results on Jul 13, 2020 Rua Life Sciences Plc announced that they will report fiscal year 2020 final results on Jul 13, 2020 
